Navigation Links
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Date:12/23/2009

insert which may be found on the Kowa Pharmaceuticals America, Inc. web page at http://www.kowapharma.com/companyLivalo.htm

About Kowa Company, Ltd. and Kowa Pharmaceuticals America, Inc.

Kowa Company, Ltd. is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products. Kowa's pharmaceutical division is focused on cardiovascular therapeutics. In the US, Kowa has two subsidiaries in the pharmaceutical business, Kowa Pharmaceuticals America, Inc. and Kowa Research Institute, Inc., located in the Research Triangle Park area of North Carolina and responsible for the clinical development of Kowa's drug candidates.

Kowa Pharmaceuticals America, Inc. is a specialty pharmaceutical company focused primarily in the area of cardiometabolic disease. The company started in 2001 as ProEthic Pharmaceuticals, Inc., and a majority stake in the company was acquired by Kowa Company, Ltd. in September, 2008. A privately held company, Kowa Pharmaceuticals America focuses its efforts on the acquisition, development, licensing and marketing of pharmaceutical products. Its lead product, LIPOFEN® (fenofibrate capsules), is indicated as adjunctive therapy to diet to reduce elevated triglycerides and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

For more information about KPA, please visit

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014  Breckenridge Pharmaceutical, Inc. announced today ... agreement with Pii (Pharmaceutics International, Inc.) ( ... and Pii expect to develop and commercialize several ... Pii will develop, manufacture and supply the products, ... under its own label.  The drugs, comprised of ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. ... Piper Jaffray Healthcare Conference in New York ... a.m. PDT . Dr. Helen Torley , President ... The presentation will be webcast through the "Investors" section ... recording will be made available for 90 days following the ...
(Date:11/24/2014)...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today ... and update at the Piper Jaffray 26 th Annual ... Eastern Time (5:30 a.m. Pacific Time), at The New York ... A live audio webcast of the presentation will be ... www.arenapharm.com . A replay of the presentation will be ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3
(Date:11/26/2014)... (PRWEB) November 26, 2014 With a ... surgeon Dr. Steven Meier has enhanced the user ... current and prospective patients an online destination for orthopedic ... excited to present the new and improved version of ... make it easier than ever for current and prospective ...
(Date:11/26/2014)... 26, 2014 GI for Life announced ... reductions in prices of their popular nutritional supplements: ... D3 . Discounts of 40% will be offered ... for Life’s proprietary ColoVite supplement is a scientifically formulated ... colon health. One easy-to-take colon vitamin with ALL the ...
(Date:11/26/2014)... 2014 Sonru, the video interviewing specialist, ... Operating Officer and Chief Marketing Officer, in addition to ... , Jeff Jones has been appointed as Chief Operating ... the role of Chief Marketing Officer. , Mr Jones ... 25-year career includes senior roles with The Walt Disney ...
(Date:11/26/2014)... 2014 Anthropologists have identified concrete ... and stopping Ebola, improve international support, and pave ... in West Africa. , The report, “Strengthening ... Anthropologists Offer Insights,” will be made public during ... Association (AAA), Fri., Dec. 5, 11 a.m., at ...
(Date:11/26/2014)... 26, 2014 Medical suction and vacuum ... of 5. This score represents steady growth in the ... to 2014 as a result of swelling demand for ... which are largely considered nondiscretionary. IBISWorld market research analyst, ... have some degree of flexibility, given the low level ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4
... Karolinska Institutet sheds light on the pathological course of ... to display amyloids demonstrable with a PET scanner has ... after death. One pathological characteristic of Alzheimer,s ... proteins to form amyloid plaques. However, it is not ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Babies born ... of stress hormones, decreased muscle tone and other neurological and ... are that [the infants] are either more sensitive to stress ... less able to shut down their stress response," lead investigator ...
... A one-year follow-up study on seniors who participated in a ... as savings for the healthcare system. The research, conducted at ... Health and the University of British Columbia, is published today ... study is the first to examine whether both cognitive and ...
... News) -- About 40 percent of patients with incurable ... treatments, finds a new study. German researchers asked ... gliomas (tumors) about their use of alternative therapies. ... homeopathy, 31 percent used vitamin supplements and 29 percent ...
... Reporter , MONDAY, Dec. 13 (HealthDay News) -- Taxing ... minimal weight loss, although the revenues generated could be ... Adding to a spate of recent studies examining ... Duke-National University of Singapore (NUS) Graduate Medical School looked ...
... Expression of a toxic RNA that leads to Fragile X ... according to new research from U-M Medical School scientists., In ... Of Science Genetics, U-M,s Peter K. Todd, M.D., Ph.D., led ... toxic messenger RNA (mRNA) seen in the brains of those ...
Cached Medicine News:Health News:Unique case study on Alzheimer's disease 2Health News:Depression During Pregnancy Might Affect Baby 2Health News:Strength training for seniors provides cognitive function, economic benefits: VCH-UBC study 2Health News:Many Brain Tumor Patients Turn to Alternative Therapies 2Health News:Taxing Sodas Won't Spur Much Weight Loss, Study Says 2Health News:Taxing Sodas Won't Spur Much Weight Loss, Study Says 3Health News:U-M researchers discover way to block neurodegeneration in an adult form of Fragile X syndrome 2
... new age of non-surgical facial contouring materials. ... long-term results for various applications with exceptional ... superior versatility for a wide variety of ... saves time and money for both you ...
... Response is a whole blood ... be used at the point-of-care. ... screen and data management features, ... options. QC and operator lockout ...
... a revolutionary scientific breakthrough for controlling unsightly ... Cream permits you to spot reduce in ... can rid yourself of those unwanted lumps ... to your thigh, waist, tummy, or chin ...
... has been developed specifically to fight Cellulite ... and hips. It does this by stimulating ... fluids in your body, which then are ... daily, for about 15 minutes each treatment. ...
Medicine Products: